Stockscreener 앱 받기
174.90
1.39%
2.40
시간 외 거래:
174.90
전일 마감가:
$172.50
열려 있는:
$173.77
하루 거래량:
915.70K
Relative Volume:
0.97
시가총액:
$8.61B
수익:
$4.02B
순이익/손실:
$-142.16M
주가수익비율:
-59.16
EPS:
-2.9563
순현금흐름:
$518.49M
1주 성능:
+5.43%
1개월 성능:
-2.01%
6개월 성능:
+2.59%
1년 성능:
+19.80%
1일 변동 폭
$171.66
$176.20
1주일 범위
$153.25
$176.20
52주 변동 폭
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
174.90 | 8.49B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
494.54 | 182.60B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.79 | 134.18B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
564.66 | 44.63B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.54 | 32.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.89 | 29.21B | 3.17B | 642.63M | 516.49M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
CRL Technical Analysis & Stock Price Forecast - Intellectia AI
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
AI-led selloff in contract research firms may be misjudging disruption risk - Reuters
[ARS] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing - Stock Titan
Charles River (NYSE: CRL) details CEO transition, 4.8M-share incentive plan in 2026 proxy - Stock Titan
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories Stock: A Key Player in Drug Discovery Services for North American Investo - AD HOC NEWS
Valuation Update: Will Charles River Laboratories International Inc benefit from green energy policies2026 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Charles River Laboratories International Inc (CRL) Shares Down 3 - GuruFocus
Why is Charles River (CRL) down 6.8% since last earnings report? - msn.com
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - Yahoo Finance
Charles River Laboratories stock: Is CRL underperforming the healthcare sector? - MSN
Assenagon Asset Management S.A. Increases Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
FinancialContentRadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know - FinancialContent
Charles River Laboratories International Inc (CRL) Shares Gap Do - GuruFocus
Riverbridge Partners LLC Reduces Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Top Charles River Laboratories International (CRL) Competitors 2026 - MarketBeat
Charles River Laboratories Experiences Evaluation Revision Amid Mixed Market Signals - Markets Mojo
Vanguard realigns holdings; Charles River (NYSE: CRL) shows 0% stake - Stock Titan
Volume Report: Will Charles River Laboratories International Inc benefit from green energy policies2026 Recap & Smart Investment Allocation Insights - baoquankhu1.vn
U.S. Sterility Testing Market Set to Boom Rapidly by 2033 | Thermo - openPR.com
Charles River extends gains as Evercore upgrades after Q1 beat - msn.com
SG Americas Securities LLC Invests $36.26 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Nordea Investment Management AB Grows Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs stock faces technical shift to sideways amid mixed signals and 2026 guidance - AD HOC NEWS
Contravisory Investment Management Inc. Takes $1.22 Million Position in Charles River Laboratories International, Inc. $CRL - Defense World
Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector? - Yahoo Finance
Could Charles River (CRL) Using Locus Cell Tie-Up to Reframe Its Asia-Pacific Growth Strategy? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
10,284 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Oliver Luxxe Assets LLC - MarketBeat
JPMorgan Chase & Co. Raises Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Why Is Charles River (CRL) Down 6.8% Since Last Earnings Report? - Yahoo Finance
Confluence Investment Management LLC Has $21.07 Million Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
FDA issues guidance on alternatives to animal testing - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Sees Significant Increase in Short Interest - MarketBeat
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Charles River Laboratories International (CRL) faces biotech R&D spending headwinds - MSN
National Bank of Canada FI Grows Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River announces divestitures, updates guidance - MSN
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
CRL,PBE Volatility & Greeks - Finviz
Charles River Laboratories International, Inc. $CRL Holdings Reduced by Iron Triangle Partners LP - MarketBeat
Gotham Asset Management LLC Acquires 46,594 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
자본화:
|
볼륨(24시간):